THE NEXT GENERATION OF CANCER DIAGNOSTICS
HMRC-Approved EIS Opportunity | Invest from £12,000
Advancing cancer monitoring through a simple blood test
Frontier Diagnostics is developing precision diagnostics to help clinicians detect circulating tumour cells, monitor disease progression and assess treatment response — providing valuable insights through a simple blood sample.
An operational, ISO 15189-accredited laboratory and commercial partnerships across Europe and Asia underpin its growth strategy.
INVESTMENT HIGHLIGHTS
| • | £25.5M valuation |
| • | HMRC-approved EIS opportunity |
| • | Minimum investment: £12,000 |
| • | Operational, ISO 15189-accredited laboratory |
| • | Distribution partnerships across Europe and Southeast Asia |
| • | Dual revenue model: diagnostic testing, hardware and consumables |
| • | Targeted strategic exit: Q4 2030 |
EXPERTISE MEETS OPPORTUNITY
Led by Dr Martin Burow, former Head of Asia Pacific at Thermo Fisher Scientific, Frontier Diagnostics aims to bring innovative circulating tumour cell technology into clinical practice.
EIS TAX ADVANTAGES
Eligible investors may benefit from 30% Income Tax Relief, Capital Gains Tax deferral, tax-free gains and loss relief, subject to individual circumstances and applicable conditions.
EXPLORE THE OPPORTUNITY
Discover the technology, business model and investment proposition.
Alternatively, request the financial model or arrange an introductory call with the management team.
|